These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 26536363)

  • 21. Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis.
    Hasnain G; Shomik MS; Ghosh P; Rashid MO; Hossain S; Hamano S; Mondal D
    Am J Trop Med Hyg; 2016 Dec; 95(6):1383-1385. PubMed ID: 27672208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
    Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
    PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycoproteins in circulating immune complexes are biomarkers of patients with Indian PKDL: A study from endemic districts of West Bengal, India.
    Jaiswal P; Datta S; Sardar B; Chaudhuri SJ; Maji D; Ghosh M; Saha B; Mukhopadhyay S
    PLoS One; 2018; 13(2):e0192302. PubMed ID: 29420575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic Arsenic Exposure and Risk of Post Kala-azar Dermal Leishmaniasis Development in India: A Retrospective Cohort Study.
    Das S; Mandal R; Rabidas VN; Verma N; Pandey K; Ghosh AK; Kesari S; Kumar A; Purkait B; Lal CS; Das P
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005060. PubMed ID: 27776123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis.
    Ganguly S; Das NK; Panja M; Pal S; Modak D; Rahaman M; Mallik S; Guha SK; Pramanik N; Goswami R; Barbhuiya JN; Saha B; Chatterjee M
    J Infect Dis; 2008 Jun; 197(12):1762-71. PubMed ID: 18444882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
    Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
    Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia.
    Palić S; Chu WY; Sundar S; Mondal D; Das P; Pandey K; Raja S; Rijal S; Roseboom IC; Hamadeh A; Malik PRV; Beijnen JH; Huitema ADR; Sjögren E; Alves F; Dorlo TPC
    J Antimicrob Chemother; 2024 Jul; 79(7):1547-1554. PubMed ID: 38727613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of rK39 for diagnosis of post kala-azar dermal leishmaniasis in Nepal.
    Das ML; Deb M; Karki BM; Sarif M; Khanal B; Bhattacharya SK; Agrawal S; Koirala S
    Southeast Asian J Trop Med Public Health; 2007 Jul; 38(4):619-25. PubMed ID: 17882997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification and glycobiological characterization of circulating immune complexes in patients with visceral leishmaniasis and post kala azar dermal leishmaniasis.
    Datta S; Modak D; Sarkar S; Saha B; Mukhopadhyay S
    Indian J Exp Biol; 2015 Jun; 53(6):321-8. PubMed ID: 26155670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
    Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
    Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential decline in Leishmania membrane antigen-specific immunoglobulin G (IgG), IgM, IgE, and IgG subclass antibodies in Indian kala-azar patients after chemotherapy.
    Anam K; Afrin F; Banerjee D; Pramanik N; Guha SK; Goswami RP; Saha SK; Ali N
    Infect Immun; 1999 Dec; 67(12):6663-9. PubMed ID: 10569788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis.
    Thakur CP; Narain S; Kumar N; Hassan SM; Jha DK; Kumar A
    Ann Trop Med Parasitol; 1997 Sep; 91(6):611-6. PubMed ID: 9425363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
    Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
    Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.
    Sundar S; Singh A; Chakravarty J; Rai M
    ScientificWorldJournal; 2015; 2015():414378. PubMed ID: 25685839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of anti-gal enzyme-linked immunosorbent assay for the diagnosis of Indian post-kala-azar dermal leishmaniasis.
    Datta S; Ghosh M; Sarkar S; Saha B; Mukhopadhyay S
    Indian J Dermatol Venereol Leprol; 2019; 85(6):578-589. PubMed ID: 31397399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: an open clinical trial and case-control study protocol.
    Mondal D; Hasnain MG; Hossain MS; Ghosh D; Ghosh P; Hossain H; Baker J; Nath R; Haque R; Matlashewski G; Hamano S
    BMJ Open; 2016 May; 6(5):e010050. PubMed ID: 27188804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genome wide comparison of Leishmania donovani strains from Indian visceral leishmaniasis and para-kala-azar dermal leishmaniasis patients.
    Sarraf NR; Mukhopadhyay S; Banerjee A; Das AK; Roy S; Chakrabarti S; Manna M; Saha P
    Acta Trop; 2021 Nov; 223():106086. PubMed ID: 34389331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.
    Mishra J; Madhubala R; Singh S
    Parasitol Res; 2013 Mar; 112(3):1001-9. PubMed ID: 23242321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic and prognostic potential of a competitive enzyme-linked immunosorbent assay for leishmaniasis in India.
    Chatterjee M; Jaffe CL; Sundar S; Basu D; Sen S; Mandal C
    Clin Diagn Lab Immunol; 1999 Jul; 6(4):550-4. PubMed ID: 10391861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.
    Singh R; Kumar D; Ramesh V; Negi NS; Singh S; Salotra P
    J Infect Dis; 2006 Aug; 194(3):302-6. PubMed ID: 16826477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.